Fig. 6: HK2 together with SENP1 upregulation associates poor outcome and worse chemotherapy response in prostate cancer patients.

a Representative images of immunohistochemistry staining of HK2 and SENP1 in Renji prostate cancer tissue microarray. Scores were calculated by intensity and percentage of stained cells. Scale bar, 600 μm. b Kaplan–Meier survival analysis in HK2 high subgroup of prostate cancer biochemical progression-free survival (BPFS) defined as SENP1 low or high expression, using Renji tissue microarray cohort. Statistical difference was determined by a two-sided log-rank test. NS not significant. c Relationship between SENP1 staining and Gleason Score in HK2 low or high subgroup, using Renji tissue microarray cohort. Gleason Score was divided in low ≤6, medium = 7, and high 8–10. The distribution of high Gleason Score increased in SENP1 and HK2 both high group. Statistical significance was measured by the chi-square test. NS not significant. d The percentage of biochemical recurrence <1 or ≥1 year of docetaxel-based neoadjuvant chemohormonal therapy prostate cancer patients (n = 48 samples), stratified by HK2 and SENP1 expression. Statistical significance was measured by the chi-square test. NS not significant. e Schematic diagrams illustrating the critical role of HK2 SUMOylation in prostate cancer cell docetaxel treatment. Source data are provided as a Source Data file.